Evaluation of SCOUT DS in Subjects With Type 2 Diabetes
TCOYD
An Evaluation of a Non-invasive Diabetes Screening Device in Subjects With Type 2 Diabetes
1 other identifier
observational
270
1 country
1
Brief Summary
The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 28, 2011
CompletedFirst Posted
Study publicly available on registry
May 2, 2011
CompletedDecember 4, 2012
December 1, 2012
Same day
April 28, 2011
December 3, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Validation of SCOUT DS algorithm for detecting known type 2 diabetes
Collect SCOUT DS and Hemoglobin A1c measurements of subjects with Type 2 Diabetes
1 day
Study Arms (1)
Those with Type 2 diabetes
All subjects have been diagnosed with type 2 diabetes.
Eligibility Criteria
Attendees of the Taking Control of Your Diabetes Health Fair, San Diego CA Convention Center
You may qualify if:
- Age greater than or equal to 18 years
- Self-reported diagnosis of type 2 diabetes
You may not qualify if:
- Not diagnosed with type 2 diabetes
- Diagnosed with type 1 diabetes
- Known to be pregnant (Self Reported)
- Receiving dialysis or having known renal compromise
- Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
- Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VeraLight, Inc.lead
Study Sites (1)
San Diego Convention Center
San Diego, California, 92111, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martin L Kabongo, MD,PhD
Accelovance San Diego
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2011
First Posted
May 2, 2011
Study Start
October 1, 2010
Primary Completion
October 1, 2010
Study Completion
October 1, 2010
Last Updated
December 4, 2012
Record last verified: 2012-12